



# **Programme**

## Thursday, 21 May 2026

#### **CONFERENCE ROOM**

| 12:00-14:30 | Beginning of the conference Introductory lecture: Neurocutaneous diseases — challenges and successes  Session I. Tuberous Sclerosis Complex (TSC): Drug- resistant epilepsy and its consequences Epilepsy and its complications in TSC Treatment of drug-resistant epilepsy in TSC — new antiseizure drugs Treatment of agitation and behavioral disorders in TSC — use of cannabinoids Ketogenic diet in drug-resistant epilepsy Vagus nerve stimulator and surgical treatment of epilepsy in TSC                                 |
|-------------|--|
| 14:30-15:00 | Coffee break   |
| 15:00-16:00 | Corporate session I  |
| 16:15-19:05 | Session II. Tuberous sclerosis complex: Organ changes Subependymal giant cell astrocytoma (SEGA) brain tumors and their treatment — neurosurgical and mTOR inhibitors (everolimus and rapamycin) Skin symptoms in tuberous sclerosis and their treatment mTOR inhibitors in the treatment of skin lesions Nephrological complications of tuberous sclerosis complex — treatment of angiomyolipoma tumors Treatment of ophthalmological symptoms in TSC Treatment of manifestations of cardiac tumors — surgery and mTOR inhibitors |
| 20:00-22:00 | Dinner   |

## Friday, 22 May 2026

#### **CONFERENCE ROOM**

| 08:30-10:30 | Session III. Neurofibromatosis Type 1 (NF1) Evolution of NF1 diagnostic criteria Neurological symptoms of NF1 and their treatment Treatment of skin lesions and plexiform neurofibromas in NF1 Treatment of neurofibromas with selumetinib                           |
|-------------|--|
| 10:30-11:00 | Coffee break   |
| 11:00-12:30 | Session IV. NF1 Treatment of optic nerve gliomas in NF1 Arterial hypertension and treatment in NF1 NF1 genetics — other forms of neurofibromatosis Legius syndrome   |
| 12:30-13:30 | Lunch and poster session   |
| 13:30-14:30 | Pharma session II  |
| 14:45-16:45 | Session V. Sturge-Weber syndrome Sturge-Weber syndrome: epilepsy, paresis, brain bleeding — treatment Treatment of vascular mole on the face in patients with Sturge-Weber syndrome ADHD and Conduct Disorders   |
| 16:45-17:15 | Coffee break   |
| 17:15-19:00 | Session VI. Other rare skin and nerve diseases Jadassohn syndrome: treatment of neurological and skin lesions — laser therapy Hippel-Lindau disease — kidney and brain tumors and retinal detachment Sleep disorders in patients with cutaneous and nervous diseases |
| 20:00-22:00 | Gala dinner  |

## Saturday, 23 May 2026

#### **CONFERENCE ROOM**

| 08:30-10:00 | Session VII. New techniques in the diagnosis and treatment of neurocutanous disorders Neurocutanous disorders in the era of large-scale genetic testing New techniques for the treatment of ocular lesions in neurocutaneous diseases New dermatological techniques in the treatment of skin lesions in neurocutaneous diseases Radiological methods in the diagnosis of organ changes in cutaneous and nervous diseases |
|-------------|--|
| 10:00-10:30 | Coffee break   |
| 10:30-11:30 | Session VIII. Highlights, posters winners, and Conference summary and conclusion   |